Physiomics Share Discussion Threads

[davevt] 15/11/2018 11:13

Yet behind the ears badger, we have had plenty of modest contracts, and every one brought the price down.

Contracts only happen when pharmas have a drug that they need dose prediction for, and will sub it out to pyc. Hence why contracts are so few and far between, it's not like they are finalising completed drugs that often.

And when your company looks like this, it's why the pharmas don't take pyc too seriously. Jim and his tablecloth and news paper stand...

[badger60] 15/11/2018 01:33

A relatively modest contract would be worth multiples to the share price.


Mkt cap circa 3mio.
Only 72mio shares in issue.
Nearly 70% of shares held in disclosed nominee accounts.
4 Recent income generating deals. Merck agreement.
Grant income.
No problem raising equity.
The company is debt free and has cash reserves.



PYC has already established itself as having growth potential by securing an agreement with a major pharma and grant awards along with other small income generating deals...... and going forward a relatively modest deal in the low mio's will catapult the share price by many multiples.





"We are very pleased to report on a year when we generated the highest total income in the Company's history. Having secured the agreement with Merck KGaA in November 2017, we were able to turn our attention to our pipeline and, leveraging the publicity generated by the Merck deal we converted two large pharmaceutical clients and a biotech client in the second half of the financial year, with a further biotech client landing after the year end.

In addition, the Company won a second Innovate UK grant in consecutive years in the field of personalised cancer treatment targeting prostate cancer.

The progress during the year was the result of increased marketing efforts and the pipeline of new business that has been built up since Dr Millen joined the company in 2016."

[spacedust] 14/11/2018 17:36

Why is it valued at millions of pounds when it should be 500k then

[spacedust] 13/11/2018 15:09

Our revenues are greater than 0.5m right?

[badger60] 13/11/2018 10:17

A compelling argument...so just added a few more...;+)

[the stigologist] 13/11/2018 09:34

A little video on new AI medtech IPO Sensye (SENS)



SENS Mkt Cap £240m
PYC Mkt Cap £3m

SENS Revenue £0m
PYC Revenue £0.5m

Like SENS Physiomics does have existing links to Oxford Uni and the NHS

Unlike SENS Physiomics actually does have deals with Big Pharma and Revenues!

I reckon PYC is 10x undervalued right now

If the 'market' doesn't recognise that the deep pocketed new players in AI medtech like Google will do !

What Sensyne highlight is the value of being a UK company with 'privileged' access to the NHS and the incredible datasets a unified State health service has access to. This is not something US players can gain easy access to. The value of UK players to US entrants will be huge. That strategic significance is simply not reflected in any way whatsoever in PYC's current £3m Market Cap.

[badger60] 13/11/2018 01:28

Funnily enough Hemogenyx was up 11% as well ......on the back of great recent funding and business development newsflow with huge upside value potential. Like PYC, I wouldn't want to be short of that one either.........

[zen12] 12/11/2018 14:08

Correction - will host a stand.
Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for
Research and Treatment of Cancer (“EORTC”) acts as a hub for a network of over 930 institutions in 30 countries focused on translational and clinical cancer research.

The Symposium is co-hosted by EORTC, the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), and brings together academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development.

Physiomics will host a stand for the full duration of the event, bringing it into contact with representatives of key academic and commercial organisations involved in the research and development of new cancer diagnostics and therapeutics.

[badger60] 12/11/2018 12:20

I certainly wouldn't want to be short.......

[the stigologist] 12/11/2018 11:30

They aren't presenting at Conference as far as i'm aware, just got a booth in the exhibition. Looks like early stage market seeding activity to me.

[zen12] 12/11/2018 11:29

Looking ready for a break out - PyC are also in conference tomorrow.

[nobbygnome] 12/11/2018 10:46

Chart looking good for a further rise....I agree 5p is a good short term target

[the stigologist] 12/11/2018 10:18

SENS (Sensyne) Mkt Cap £240m Rev : £0m
RENX (Renalytix) Mkt Cap £70m Rev : £0m
PYC (Physiomics) Mkt Cap £3m Rev : £0.5m

[spacedust] 12/11/2018 10:14

5.5p first looking at the charts

[strongbuy] 12/11/2018 10:11

30p coming again sooon

[the stigologist] 12/11/2018 09:56

strong
only undervalued by about 10x

[the stigologist] 11/11/2018 12:43

If Merck KGaA spending 500k a year imagine the potential market size amongst much larger Pharmas.

[the stigologist] 11/11/2018 12:42

Merck KGaA one of most innovative pharmas put there. Expect other bigger players to follow their lead and sign up with PYC

[davevt] 09/11/2018 16:55

That's cos you're an idiot badger. Keep buying.

[badger60] 09/11/2018 16:31

Added a few more today.

[spacedust] 09/11/2018 16:16

4.3p fin8sh would be awesome

[spacedust] 09/11/2018 12:08

BHP Mkt Cap £Billions Rev : £Bn
GLEN Mkt Cap £Billions Rev : £Bn
Spacedust mining Mkt Cap £1k Rev: 0

[davevt] 09/11/2018 11:47

Stig is on the ramp fest again, watch out, her trying to compare little old antiquated pyc with state of the art tech monsters.